The advent of combination therapy unprecedentedly shifted the paradigm of cancer treatment by reconstructing the conventional protocols. By identifying the anti-tumoral activity for different natural products, recent interest has focused on inventing the combined-modality strategies to increase the cure rates of cancer, while reducing the toxic side effects of current intensive regimens. To evaluate whether melatonin, indolic hormone produced mainly by the pineal gland, could enhance the pro-apoptotic effect of arsenic trioxide (As2O3) in breast cancer, MCF-7 cells were treated with As2O3-plus-melatonin and then the survival, proliferative rate, caspase-3 activity, and mRNA expression level of anti-apoptosis target genes of NF-κB were investigated. Our results delineated that exposure of MCF-7 cells to As2O3 not only reduced the survival of the cells, but also induced a caspsase-3-dependent apoptotic cell death. Noteworthy, an enhanced induction of apoptosis was found using As2O3 in combination with melatonin.
he therapeutic approaches in breast cancer, as the most common malignancy in womankind in term of morbidity and mortality (1) , still remain an unsolvable dilemma; therefore, the entrance of the novel anti-tumoral agents in combination with chemotherapy or radiotherapy turns to be groundbreaking for more efficient treatment.
During the last decade, identifying the potent anticancerous property of arsenic trioxide (As2O3) revitalizes the popularity of this agent as an effective chemotherapeutic drug not only for hematologic malignancies but also for solid tumors (2) . An overwhelming number of studies imply that As2O3 exerts its variegated apoptotic effects through various mechanisms including modulation of the intracellular glutathione redox system (3), induction of mitotic arrest (4) , DNA damage and inhibition of DNA repair (5) . Despite its prodigious anti-tumoral activities, the clinical use of this agent became restricted due to the toxic side effects of long-term intake of high doses of As2O3. A recent renaissance of As2O3 following the novel disclosure indicating that As2O3 is an ideal agent to be used in combination therapy, has revived the interest in this ancient drug and has constructed its future direction into clinical investigations.
Melatonin, the master biologic clock neurohormone, is basically considered as the main regulator of circadian rhythm and sleep quality (6) .
Thus far, a plethora of biological actions have been reported for melatonin; however, recent investigations concerning its inhibitory impact on the development, promotion, and progression of various types of cancers, in particular, breast cancer have attracted tremendous attention (7) . In the last decades, several experimental studies have outlined that melatonin not only possess a chemo-preventive property (8) , but also exerts a pro-apoptotic activity in cancer cells mostly through generation of intercellular ROS (9, 10) . For the nonce, multiple published reports have discussed about the intensifying effect of melatonin in combination with different chemotherapeutic drugs, especially DNA damaging agents such as cis-platin (11), cyclophosphamide (12) , and doxorubicin (13) .
Based on the convergence mechanisms between melatonin and As2O3 (14, 15) , it was tempting to evaluate whether melatonin could enhance the proapoptotic effect of As2O3 in MCF-7 breast cancer cells. 
Materials and methods

Cell line and reagents
Trypan blue exclusion assay
Breast cancer-derived MCF-7 cells were seeded at the density of 450 × 10 5 cells and were incubated with various concentrations of As2O3 and melatonin, either alone or in combined modality.
After 48 h, drug treated-cells were trypsinized, centrifuged and the cell pellets were re-suspended 
MTT assay
Microculture tetrazolium assay (MTT) was applied to explore the impeding effect of As2O3, Finally, the cells were exposed to 100 μl of substrate tetramethyl-benzidine (TMB) for 3 min at room temperature and the reaction product was quantified by measuring the absorbance at 450 nm in an ELISA reader.
Median-effect analysis of drug combinations
To evaluate whether there was a synergistic effect between As2O3 and melatonin, we computed the combination index (CI) using the method developed by Chou and Talalay (16) . The dose which may be reduced in a combination for a given Values of CI and DRI after 48 h treatment of MCF-7 cells are summarized in Table 2 . remarkably increased the percentage of annexin-V cells to 2 and 5 μM for 48 h increased caspase-3 activity by 9-and 27-fold, respectively (Fig. 4a) .
Noteworthy, co-treatment of the cells with melatonin and As2O3 also resulted in apoptotic cell death through a caspase-3-dependent cascade However, similar to annexin-V staining assay data, enzymatic activation of caspase-3 significantly increased when As2O3 was used in combination with melatonin (P =0.044) (Fig. 4b) , substantiating the potentiating effect of melatonin for As2O3 treatment.
Downregulation of NF-kB anti-apoptotic target genes following cell treatment with As2O3 and melatonin
Conclusive evidence has stated that perturbed activation of NF-κB, a potent inducer of antiapoptotic genes, contributes to the process of chemo-resistance in tumor cells (19) . Our results revealed that while 2 µM As2O3 had minimal effect on NF-κB death repressor genes transcription ( Fig.5a ), physiological dose of melatonin robustly reinforced the suppressive effect of As2O3 on NF-κB downstream anti-apoptotic target genes.
As illustrated in figure 5b , when MCF-7 cells were treated with both As2O3 and melatonin, the mRNA expression levels of MCL-1, BCL-2, survivin, XIAP, and c-IAP1 reduced significantly ( Fig. 5b) . declared that melatonin may ameliorate the adriamycin-induced cardiac dysfunction through free radical scavenging or abrogating lipid peroxidation (25, 26) . Additionally, it has been indicated that melatonin enhanced the apoptotic effect of the conventional chemotherapeutic drugs, such as tamoxifen (27), cis-platin (28), and 5-fluorouracil (29 Conclusive evidence has stated that the activation of NF-κB, a potent inducer of antiapoptotic genes, could be responsible for unexpected side effects of many commonly used chemotherapeutic drugs (19) . 
Discussion
